

**12 month risk of medical encounters for congenital malformations, deformations, and chromosomal abnormalities  
in patients with comorbid T2DM and OUD  
(Comparision between matched semaglutide vs other anti-diabetes medications groups)**

Size/group	Exposure	Comparison	Cases (overall risk) (Exposure)	Cases (overall risk) (Comparison)	Risk difference (95% CI)	HR (95% CI)
2,790	semaglutide	insulin	137 (4.91%)	137 (4.91%)	−0.00% (−1.13%, 1.13%)	0.98 (0.77–1.24)
2,605	semaglutide	metformin	123 (4.72%)	123 (4.72%)	−0.00% (−1.15%, 1.15%)	1.00 (0.78–1.28)
1,751	semaglutide	DPP−4i	77 (4.40%)	90 (5.14%)	−0.74% (−2.15%, 0.67%)	0.84 (0.62–1.13)
2,361	semaglutide	SGLT2i	110 (4.66%)	119 (5.04%)	−0.38% (−1.61%, 0.84%)	0.90 (0.70–1.17)
2,128	semaglutide	SU	89 (4.18%)	97 (4.56%)	−0.38% (−1.60%, 0.85%)	0.91 (0.68–1.21)
723	semaglutide	TZD	24 (3.32%)	20 (2.77%)	0.55% (−1.22%, 2.32%)	1.18 (0.65–2.13)
2,406	semaglutide	other GLP−1RAs	113 (4.70%)	135 (5.61%)	−0.91% (−2.16%, 0.34%)	0.83 (0.65–1.07)
1,186	semaglutide	Liraglutide	65 (5.48%)	70 (5.90%)	−0.42% (−2.29%, 1.44%)	0.93 (0.66–1.30)
2,204	semaglutide	Dulaglutide	99 (4.49%)	108 (4.90%)	−0.41% (−1.66%, 0.84%)	0.91 (0.69–1.19)

0.10 0.20 0.40 0.80 2.0 4.0 10.00  
**Hazard Ratio (HR)**